Monospecific monoclonal antibodies against human transcription factors

(same原文） 这是一个创建生产中心的建议，该中心能够实施一个管道，包括 人转录因子免疫原的获得和评价， 单特异性单克隆抗体（mMAb），以及生物化学表征和验证 这些蛋白质捕获（亲和）试剂。 我们强调的优势，高吞吐量和可扩展性，以实现在我们的 生产努力，并提出工艺改进的发展，从而提高成本 在获奖期间的质量。我们将保持一定程度的科学灵活性， 开发生产针对不易处理的转录因子蛋白的亲和试剂的方法 目标是在生产过程中确定的。 最后，我们提出了一个可行的分配计划符合NIH的政策，利用现有的 开发性杂交瘤单克隆库，确保广泛的可用性和 未来使用试剂的可及性，具有最小的限制，与实现 这一融资举措的目标。

(same as original) This is a proposal to create a production center capable of implementing a pipeline that includes acquisition and evaluation of human transcription factor immunogens, production and selection of monospecific Monoclonal antibodies (mMAbs), and biochemical characterization and validation of these protein capture (affinity) reagents. We emphasize the advantages of high throughput and scalability to be achieved within our production effort, and propose the development of process improvements, thereby improving cost and quality over the duration of the award. We will maintain a degree of scientific flexibility to develop approaches to producing affinity reagents to less tractable transcription factor protein targets as they are identified in the course of production. Finally we propose a viable distribution plan consistent with NIH policies, utilizing the existing Developmental Hybridoma Monoclonal Bank, which ensures broad availability and wide accessibility for future use of the reagents with minimal constraints, consistent with achieving the goals of this funding initiative.